We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · June 14, 2021

A Phase I Study of Alpelisib + Trastuzumab + LJM716 for PIK3CA-Mutated HER2+ Metastatic Breast Cancer

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
A Phase I Study of Alpelisib in Combination With Trastuzumab and LJM716 in Patients With PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer
Clin. Cancer Res 2021 May 04;[EPub Ahead of Print], K Jhaveri, JZ Drago, PD Shah, R Wang, F Pareja, F Ratzon, A Iasonos, S Patil, N Rosen, MN Fornier, NT Sklarin, S Chandarlapaty, S Modi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading